VALN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

5.420

Open

5.400

VWAP

5.36

Vol

17.88K

Mkt Cap

508.25M

Low

5.300

Amount

95.84K

EV/EBITDA(TTM)

--

Total Shares

94.82M

EV

530.09M

EV/OCF(TTM)

--

P/S(TTM)

2.19

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Show More

Events Timeline

(ET)

2026-06-04

17:10:00

Valneva Files to Sell 31.79M Ordinary Shares

2026-03-23 (ET)

2026-03-23

06:50:00

Pfizer and Valneva Announce Lyme Disease Vaccine Trial Results

2026-03-18 (ET)

2026-03-18

08:20:00

Elaris Signs Exclusive Global License Agreement with Valneva

2026-01-19 (ET)

2026-01-19

14:20:00

Valneva Voluntarily Withdraws Ixchiq Vaccine Applications

2025-12-31 (ET)

2025-12-31

11:50:00

Valneva and Serum Institute of India Terminate Chikungunya Vaccine License Agreement

2025-12-10 (ET)

2025-12-10

11:50:00

Valneva Reports Positive Final Data for IXCHIQ Vaccine

News

Newsfilter

06-04Newsfilter

Valneva SE Announces 2026 Annual General Meeting Details

Newsfilter

05-28Newsfilter

Valneva to Present at Multiple Investor Conferences

seekingalpha

05-13seekingalpha

Valneva Adjusts 2026 Financial Outlook Amid Vaccine Uptake Decline

Newsfilter

05-13Newsfilter

Valneva Reports Q1 2026 Financial Results and Updates Guidance

Newsfilter

05-05Newsfilter

Valneva SE to Report Q1 2026 Financial Results on May 13

PRnewswire

05-01PRnewswire

Pomerantz LLP Investigates Valneva for Securities Fraud

2 Analyst Rating

Wall Street analysts forecast VALN stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.55

Averages

10.28

High

13.00

Current: 0.000

Low

7.55

Averages

10.28

High

13.00

Goldman Sachs

analyst

Neutral -> Sell

downgrade

$4.90

AI Analysis

2026-04-22

Reason

Goldman Sachs

analyst

Price Target

$4.90

AI Analysis

2026-04-22

downgrade

Neutral -> Sell

Reason

Goldman Sachs downgraded Valneva to Sell from Neutral with a $4.90 price target. Following multiple data disappointments, the company's outlook is "challenging and comes with significant uncertainty," the analyst tells investors in a research note. The VALOR trial update creates an uncertain path to approval Goldman remains cautious on Valneva's market opportunity for its Lyme disease vaccine candidate PF-07307405, the analyst tells investors in a research note.

Guggenheim

Buy

to

Buy

downgrade

$13 -> $11

2026-04-16

Reason

Guggenheim

Price Target

$13 -> $11

2026-04-16

downgrade

Buy

to

Buy

Reason

Guggenheim lowered the firm's price target on Valneva to $11 from $13 and keeps a Buy rating on the shares. The firm adjusted estimates as part of a Q1 earnings preview for commercial-stage companies in its biotechnology coverage.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VALN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Valneva SE (VALN.O) is 666.67, compared to its 5-year average forward P/E of -169.64. For a more detailed relative valuation and DCF analysis to assess Valneva SE's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-169.64

Current PE

666.67

Overvalued PE

561.42

Undervalued PE

-900.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.61

Current EV/EBITDA

-2.81

Overvalued EV/EBITDA

50.50

Undervalued EV/EBITDA

-55.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.67

Current PS

1.74

Overvalued PS

5.00

Undervalued PS

2.34

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what penny stocks to buy pre market 4/1/26

Intellectia · 14 candidates

Market Cap: 100.00M - 2.00BRegion: USVolume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEPre Market Price Change: $3.00 - $20.00

Ticker

Name

Market Cap$

Tilray Brands Inc

753.80M

Omeros Corp

748.71M

Vor Biopharma Inc

871.44M

Valneva SE

542.98M

Soleno Therapeutics Inc

1.73B

Sangamo Therapeutics Inc

102.28M

Whales Holding VALN

Novo Holdings A/S

General American Investors Company, Inc.

Bpifrance Participations SA

CNP Assurances SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Valneva SE (VALN) stock price today?

The current price of VALN is 5.36 USD — it has decreased -0.56

What is Valneva SE (VALN)'s business?

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

What is the price predicton of VALN Stock?

Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is10.28 USD with a low forecast of 7.55 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Valneva SE (VALN)'s revenue for the last quarter?

Valneva SE revenue for the last quarter amounts to NaN USD, decreased

What is Valneva SE (VALN)'s earnings per share (EPS) for the last quarter?

Valneva SE. EPS for the last quarter amounts to USD, decreased

How many employees does Valneva SE (VALN). have?

Valneva SE (VALN) has 676 emplpoyees as of June 17 2026.

What is Valneva SE (VALN) market cap?

Today VALN has the market capitalization of 508.25M USD.